1. Home
  2. CLLS vs PROF Comparison

CLLS vs PROF Comparison

Compare CLLS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$3.27

Market Cap

384.3M

Sector

Health Care

ML Signal

HOLD

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

HOLD

Current Price

$5.06

Market Cap

270.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLLS
PROF
Founded
1999
N/A
Country
France
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
384.3M
270.7M
IPO Year
2014
2017

Fundamental Metrics

Financial Performance
Metric
CLLS
PROF
Price
$3.27
$5.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$8.50
$12.00
AVG Volume (30 Days)
43.9K
256.9K
Earning Date
03-19-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.89
EPS
N/A
1.41
Revenue
N/A
$16,098,000.00
Revenue This Year
$40.37
$115.41
Revenue Next Year
N/A
$60.63
P/E Ratio
N/A
$3.65
Revenue Growth
N/A
50.73
52 Week Low
$1.10
$3.90
52 Week High
$5.48
$8.95

Technical Indicators

Market Signals
Indicator
CLLS
PROF
Relative Strength Index (RSI) 37.93 31.81
Support Level $3.32 $4.09
Resistance Level $3.83 $5.96
Average True Range (ATR) 0.21 0.51
MACD -0.02 -0.10
Stochastic Oscillator 15.54 6.34

Price Performance

Historical Comparison
CLLS
PROF

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

Share on Social Networks: